Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

New NHS data suggests weight-loss jabs like Mounjaro could reduce sick days by a third and save taxpayers £5bn a year. But ...

THE NHS is set to dish out Mounjaro prescriptions to more patients, as private clinics prepare to double their prices from ...

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh ...

The company said it was reviewing Mounjaro pricing with other governments and expected to make similar adjustments in certain ...

As Mounjaro doubles in price, we look at whether there’s another, cheaper way to suppress your appetite. By nutritionist ...

To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original ...

COMMENT: The astronomical rise in weight-loss drug prices caused by Trump’s tariffs could have a significant – and dangerous ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...